Zhou Xiao-Ping, Hampel Heather, Roggenbuck Jennifer, Saba Nabil, Prior Thomas W, Eng Charis
Clinical Cancer Genetics and Human Cancer Genetics Programs, The Ohio State University, 420 W. 12th Avenue, Columbus, OH 43210, USA.
J Mol Diagn. 2002 May;4(2):114-7. doi: 10.1016/S1525-1578(10)60690-3.
Germline mutations in the PTEN/MMAC1/TEP1 tumor suppressor gene cause Cowden syndrome (CS), a hereditary hamartoma-tumor syndrome with an increased risk of breast, thyroid, and endometrial cancers, and seemingly unrelated developmental disorders, such as Bannayan-Riley-Ruvalcaba (BRR) syndrome, Proteus, and Proteus-like syndromes. Data to date suggest that irrespective of the clinical presentation, the identification of a PTEN mutation should trigger medical management which includes cancer surveillance. Clinic-based molecular diagnostic testing for germline PTEN mutations has been available for at least 2 years. This study reports on the finding of a previously unobserved heterozygous alteration (IVS7-15-->53del39) found in an African American individual who had features of CS. Further investigation revealed that 12 of 42 (28.6%) African American controls, but not individuals of Caucasian or Japanese origin, also carried this heterozygous 39-bp deletion in PTEN. Due to its location immediately upstream of the splicing site of exon 8, this polymorphism could be mistaken for a deleterious mutation in the PTEN.
抑癌基因PTEN/MMAC1/TEP1的种系突变会导致考登综合征(CS),这是一种遗传性错构瘤-肿瘤综合征,患乳腺癌、甲状腺癌和子宫内膜癌的风险增加,还伴有一些看似不相关的发育障碍,如班纳扬-莱利-鲁瓦尔卡巴(BRR)综合征、变形综合征和类变形综合征。迄今为止的数据表明,无论临床表现如何,PTEN突变的鉴定都应引发包括癌症监测在内的医学管理。基于临床的种系PTEN突变分子诊断检测至少已经开展了两年。本研究报告了在一名具有CS特征的非裔美国人个体中发现的一种先前未观察到的杂合性改变(IVS7-15-->53del39)。进一步调查发现,42名非裔美国人对照中有12名(28.6%)携带这种PTEN杂合性39碱基缺失,但高加索或日本血统的个体未携带。由于该多态性位于外显子8剪接位点的紧邻上游,可能会被误认为是PTEN中的有害突变。